share_log

Zeal Asset Management Ltd Sells 341,789 Shares of HUTCHMED (China) Limited (NASDAQ:HCM)

Zeal Asset Management Ltd Sells 341,789 Shares of HUTCHMED (China) Limited (NASDAQ:HCM)

熱心資產管理有限公司出售和黃醫藥(中國)有限公司(納斯達克股票代碼:HCM)341,789股
Financial News Live ·  2022/10/23 22:11

Zeal Asset Management Ltd cut its position in HUTCHMED (China) Limited (NASDAQ:HCM – Get Rating) by 44.8% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 421,140 shares of the company's stock after selling 341,789 shares during the period. HUTCHMED accounts for about 10.5% of Zeal Asset Management Ltd's investment portfolio, making the stock its 3rd biggest position. Zeal Asset Management Ltd owned 0.24% of HUTCHMED worth $5,075,000 at the end of the most recent reporting period.

根據熱情資產管理有限公司在最近向美國證券交易委員會披露的信息,該公司在第二季度將其在和黃醫藥(中國)有限公司(納斯達克代碼:HCM-GET評級)的持倉削減了44.8%。該機構投資者在此期間出售了341,789股後,持有該公司421,140股股票。和黃醫藥在熱情資產管理有限公司的投資組合中約佔10.5%,這使該股成為其第三大頭寸。截至最近一次報告期末,熱心資產管理有限公司持有和黃醫藥0.24%的股份,價值5,075,000美元。

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in HCM. Quantbot Technologies LP bought a new position in shares of HUTCHMED in the first quarter worth about $44,000. US Bancorp DE raised its stake in shares of HUTCHMED by 270.9% during the first quarter. US Bancorp DE now owns 3,687 shares of the company's stock worth $70,000 after buying an additional 2,693 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank raised its stake in shares of HUTCHMED by 5.6% during the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 16,767 shares of the company's stock worth $317,000 after buying an additional 892 shares during the last quarter. Invesco Ltd. raised its stake in shares of HUTCHMED by 18.1% during the first quarter. Invesco Ltd. now owns 17,007 shares of the company's stock worth $322,000 after buying an additional 2,609 shares during the last quarter. Finally, Asset Management One Co. Ltd. raised its stake in shares of HUTCHMED by 10.9% during the second quarter. Asset Management One Co. Ltd. now owns 17,519 shares of the company's stock worth $221,000 after buying an additional 1,724 shares during the last quarter. 27.37% of the stock is currently owned by institutional investors and hedge funds.

其他一些機構投資者和對衝基金最近也增持或減持了HCM的股份。今年第一季度,Quantbot Technologies LP購買了和黃醫藥的新頭寸,價值約44,000美元。第一季度,US Bancorp DE增持和黃醫藥股份270.9%。US Bancorp DE現在擁有3687股該公司股票,價值7萬美元,此前在上個季度又購買了2693股。蘇黎世廣東銀行在第一季度增持了5.6%的和黃醫藥股份。Zurcher Kantonalbank蘇黎世廣東銀行在上個季度額外購買了892股後,現在擁有16,767股該公司股票,價值317,000美元。景順股份有限公司在第一季度增持了18.1%的和黃醫藥股份。景順公司目前持有17,007股該公司股票,價值322,000美元,上一季度又購買了2,609股。最後,資產管理一號在第二季度增持了10.9%的和黃醫藥股份。Asset Management One Co.Ltd.現在持有17,519股該公司股票,價值221,000美元,該公司在上個季度又購買了1,724股。27.37%的股票目前由機構投資者和對衝基金持有。

Get
到達
HUTCHMED
和黃醫藥
alerts:
警報:

Analysts Set New Price Targets

分析師設定新的價格目標

HCM has been the subject of a number of recent research reports. The Goldman Sachs Group boosted their price target on shares of HUTCHMED from $14.00 to $16.00 and gave the stock a "neutral" rating in a research note on Tuesday, August 9th. StockNews.com initiated coverage on shares of HUTCHMED in a research note on Wednesday, October 12th. They issued a "hold" rating for the company.

HCM是最近一些研究報告的主題。8月9日,在週二的一份研究報告中,高盛夫婦將和黃醫藥的目標價從14.00美元上調至16.00美元,並給予該股“中性”評級。斯托克新聞網在10月12日星期三的一份研究報告中首次對和黃醫藥的股票進行了報道。他們對該公司的評級為“持有”。

HUTCHMED Stock Up 2.3 %

和黃醫藥股價上漲2.3%

Shares of NASDAQ:HCM opened at $8.93 on Friday. HUTCHMED has a 52 week low of $7.61 and a 52 week high of $36.37. The company has a 50 day moving average price of $10.91 and a two-hundred day moving average price of $12.07.
上週五,納斯達克:HCM的股價開盤報8.93美元。和黃醫藥的52周低點為7.61美元,52周高點為36.37美元。該公司的50日移動均線價格為10.91美元,200日移動均線價格為12.07美元。

About HUTCHMED

關於和黃醫藥

(Get Rating)

(獲取評級)

HUTCHMED (China) Limited discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in HongKong and internationally. It operates in Oncology/Immunology and Other Ventures segments. The company develops Savolitinib, an inhibitor for non-small cell lung cancer (NSCLC), papillary and renal cell carcinoma, colorectal cancer (CRC), and gastric cancer (GC); and Fruquintinib, an inhibitor for CRC, breast cancer, GC, endometrial cancer (EMC), NSCLC, hepatocellular carcinoma, and gastrointestinal and solid tumors.

和黃醫藥(中國)有限公司在香港和國際上發現、開發癌症和免疫疾病的靶向治療和免疫療法,並將其商業化。它在腫瘤學/免疫學和其他風險投資領域開展業務。該公司開發Savolitinib,一種治療非小細胞肺癌(NSCLC)、乳頭狀細胞癌和腎癌、結直腸癌(CRC)和胃癌(GC)的抑制劑;以及Fruquintinib,一種治療CRC、乳腺癌、GC、子宮內膜癌(EMC)、非小細胞肺癌、肝細胞癌以及胃腸道和實體腫瘤的抑制劑。

Read More

閲讀更多內容

  • Get a free copy of the StockNews.com research report on HUTCHMED (HCM)
  • Should Investors Raise a Glass to Boston Beer Company?
  • MarketBeat: Week in Review 10/17-10/21
  • The Institutions Spin Whirlpool Into Bargain Basement Territory
  • American Express Beats Earnings & Revenue Views, Raises Guidance
  • Snap Stock Falls As User Growth Slows To Single-Digits
  • 免費獲取斯托克新聞網關於和黃醫藥的研究報告
  • 投資者應該向波士頓啤酒公司舉杯嗎?
  • MarketBeat:回顧一週10/17-10/21
  • 機構將惠而浦打入廉價地下室領域
  • 美國運通業績超過盈利和收入預期,提高業績指引
  • Snap股價下跌,用户增長放緩至個位數

Receive News & Ratings for HUTCHMED Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HUTCHMED and related companies with MarketBeat.com's FREE daily email newsletter.

接受《和黃醫藥日報》的新聞和評級-在下面輸入您的電子郵件地址,即可通過MarketBeat.com的免費每日電子郵件時事通訊接收對和黃醫藥及相關公司的最新新聞和分析師評級的每日摘要。

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論